QuidelOrtho Appoints Micah Young as New CFO with $6.5M Equity Grant Amidst Financial Turnaround Efforts
Summary
QuidelOrtho announced the appointment of Micah Young, a former Masimo CFO, as its new Chief Financial Officer, effective July 6, 2026, with a compensation package including a $6.5 million restricted stock unit grant.
Key Events
-
New Chief Financial Officer Appointed
Micah Young, formerly EVP and CFO of Masimo Corporation, has been appointed as QuidelOrtho's new Chief Financial Officer, effective July 6, 2026. He brings over two decades of experience in medical technology finance.
-
Substantial Equity Compensation for New CFO
Mr. Young will receive an annual base salary of $750,000, a target annual cash bonus of 100% of base salary, a $500,000 cash sign-on bonus, and a one-time inducement restricted stock unit (RSU) grant valued at $6,500,000, vesting over three years.
-
Outgoing CFO Transition to Advisory Role
Joseph M. Busky, the current CFO, will continue in his role until July 6, 2026, and then transition to a special advisor to the CEO for up to 24 months, ensuring a smooth handover.
Analysis
QuidelOrtho has appointed Micah Young, a seasoned medical technology finance executive, as its new Chief Financial Officer. This leadership change is significant, especially following the company's recent financial underperformance, including a Q1 revenue miss, lowered guidance, and negative operating cash flow. The substantial equity grant of $6.5 million, alongside a competitive cash package, underscores the company's commitment to attracting top talent to navigate its current challenges and drive improved financial performance. The orderly transition of the outgoing CFO to an advisory role also provides continuity.
At the time of this filing, QDEL was trading at $11.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $813.9M. The 52-week trading range was $9.92 to $35.58. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.